BioRestorative Therapies, Inc.
Close on Oct 19, 2026
- Market cap
- $28.36M
- P/E (TTM)
- –
- Dividend yield
- –
About BioRestorative Therapies
Services-Misc Health & Allied Services, NEC, SIC 8090
BioRestorative Therapies, Inc. is a clinical-stage biotechnology company that develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. Its lead candidate, BRTX-100, is an autologous mesenchymal stem cell therapy targeting painful lumbosacral disc disorders and chronic cervical discogenic pain. In addition, the company develops the ThermoStem Program, which uses brown adipose-derived stem cells to treat type 2 diabetes, obesity, hypertension, and related metabolic disorders. It also operates a commercial biocosmeceuticals business offering proprietary secretome-based biologic serums to address fine lines and cosmetic skin concerns.
The company operates a research laboratory facility equipped with current Good Manufacturing Practice capabilities in Melville, New York, which also serves as the location of its principal executive offices. Its therapeutic candidates are primarily evaluated in the United States through clinical trials cleared by the Food and Drug Administration. Beyond its domestic operations, the company holds issued patents and intellectual property covering its programs across several international jurisdictions, including Europe, Israel, and Japan.
Summary of the business section of BioRestorative Therapies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioRestorative Therapies, Inc.
- Founded
- 1997
- Headquarters
- Melville, NY
- Address
- 40 Marcus Drive, Suite One
- Phone
- (631) 760-8100
- Employees
- 14, Dec 31, 2025
- Industry
- Services-Misc Health & Allied Services, NEC
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Marlton, New Jersy
Stock & identifiers
- Ticker
- BRTX
- Exchange
- Nasdaq
- IPO date
- Dec 5, 2012
- Shares outstanding
- 25M, May 14, 2026
- Public float
- $11.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Sep 8, 2026; 1-for-4000 reverse, Nov 15, 2021; 1-for-4000 reverse, Oct 27, 2021; 1-for-20 reverse, Aug 14, 2015; 1-for-20 reverse, Jul 7, 2015; 1-for-50 reverse, May 15, 2013; 1-for-50 reverse, Apr 15, 2013
- SEC CIK
- 1505497
- CUSIP
- 090655606
- ISIN
- US0906556065
- EIN
- 30-1341024
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Francisco Silva | VP of Research and Development, Director | 183,520 |
| Lance Alstodt | President, CEO, COB, Director | 187,497 |
| Robert Eugene Kristal | Chief Financial Officer | 7,994 |
| Esha Randhawa | Director | – |
| Steven Collier Brown | Director | – |
| Jatinder Dhaliwal | Director | – |
| Mika Grasso | Director | – |
| Katharyn Field | Director | – |
| Nickolay V. Kukekov | Director | 0 |
| David A. Rosa | Director | 0 |
| Patrick F. Williams | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Alstodt | $1.31M | $1.20M | $955.42K | $33 | – |
| FY2023 Alstodt | $1.25M | $754.33K | $911.15K | $40 | – |
| FY2022 Alstodt | $452.36K | $151.69K | $301.18K | $63 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We currently have 14 employees, 13 of whom are full-time employees.”
Corporate history
Events identified from SEC filings